

**HEMOSTEMIX INC.**  
Suite 1150, 707 - 7 Avenue SW  
Calgary, Alberta T2P 3H6

**NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS  
TO BE HELD ON AUGUST 31, 2022**

**NOTICE IS HEREBY GIVEN** that the annual general and special meeting (the "**Meeting**") of the holders (the "**Shareholders**") of common shares ("**Shares**") in the capital of Hemostemix Inc. (the "**Corporation**") will be held at Suite 1150, 707 – 7 Avenue SW, Calgary, Alberta, Canada via teleconference on Wednesday, August 31, 2022 at 11:00 a.m. (MST).

**TO PARTICIPATE, VOTE OR SUBMIT QUESTIONS DURING THE MEETING, PLEASE REFER TO THE FOLLOWING LINK AND DIAL-IN INSTRUCTIONS:**

Link: <https://us05web.zoom.us/j/5162813723?pwd=QlIKSTJXRvJiSHFMOctzMFM0aFpCQT09>  
Meeting ID: 516 281 3723  
Password: HEM

<b><u>ONE TAP MOBILE</u></b>	<b><u>DIAL BY YOUR LOCATION</u></b>
+16473744685, 5162813723#, *618290# Canada +16694449171, 5162813723#, *618290# US	+1 669 444 9171 US +1 647 374 4685 Canada

**The Meeting is to be held for the following purposes:**

1. to receive the audited consolidated comparative financial statements of the Corporation for the years ended December 31, 2021 and 2020, the auditor's report thereon, and the related management's discussion and analysis;
2. to fix the number of directors of the Corporation (the "**Board**") at four (4);
3. to elect the directors of the Board for the ensuing year;
4. to appoint MNP LLP, Chartered Professional Accountants, as the auditors of the Corporation and to authorize the Board to fix the auditors' remuneration; and
5. to consider and, if thought advisable, to approve, with or without amendment, an ordinary resolution, to ratify and approve the Corporation's 10% "rolling" stock option plan, as more particularly described in the accompanying Management Information Circular.

Specific details of the matters proposed to be put before the Meeting are set forth in the Management Information Circular, which accompanies this Notice of Meeting.

The record date (the "**Record Date**") for determining the Shareholders entitled to receive notice of and to vote at the Meeting is July 26, 2022. Only Shareholders whose names have been entered in the register of Shareholders at the close of business on the Record Date will be entitled to receive notice of and to vote at the Meeting. **To the extent a Shareholder transfers the ownership of any of its Shares after the Record Date and the transferee of those Shares establishes that it owns such Shares and requests, at least 10 days before the Meeting, to be included in the list of Shareholders eligible to vote at the Meeting, such transferee will be entitled to vote those Shares at the Meeting or any postponement(s) or adjournment(s) thereof.**

## **NOTE OF CAUTION Concerning COVID-19 Outbreak**

At the date of this Notice and the accompanying Information Circular, it is the intention of the Corporation to hold the Meeting at the location stated above in this Notice. We are continuously monitoring ongoing coronavirus (COVID-19) outbreak (“COVID-19”). In light of the rapidly evolving public health guidelines related to COVID-19, and the COVID-19 measures implemented by the Government of Canada, we ask shareholders to consider voting their shares by proxy and **NOT ATTEND THE MEETING IN PERSON**. Shareholders who do wish to attend the Meeting in person, should carefully consider and follow the instructions of the federal Public Health Agency of Canada: (<https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19.html>). We ask that shareholders also review and follow the instructions of any regional health authorities of the Province of Alberta, including the Alberta Health Services, and any other health authority holding jurisdiction over the areas you must travel through to attend the Meeting. Please do not attend the Meeting in person if you are experiencing any cold or flu-like symptoms, or if you or someone with whom you have been in close contact has travelled to/from outside of Canada within the 21 days immediately prior to the Meeting. All shareholders are strongly encouraged to vote by submitting their completed form of proxy (or voting instruction form) prior to the Meeting by one of the means described in the Management Information Circular accompanying this Notice.

The Corporation reserves the right to take any additional pre-cautionary measures deemed to be appropriate, necessary or advisable in relation to the Meeting in response to further developments in the COVID-19 outbreak, including: (i) holding the Meeting virtually or by providing a webcast of the Meeting; (ii) hosting the Meeting solely by means of remote communication; (iii) changing the Meeting date and/or changing the means of holding the Meeting; (iv) denying access to persons who exhibit cold or flu-like symptoms, or who have, or have been in close contact with someone who has, travelled to/from outside of Canada within the 21 days immediately prior to the Meeting; and (v) such other measures as may be recommended by public health authorities in connection with gatherings of persons such as the Meeting. Should any such changes to the Meeting format occur, the Corporation will announce any and all of these changes by way of news release, which will be filed under the Corporation’s profile on SEDAR at [www.sedar.com](http://www.sedar.com). We strongly recommend you check the Corporation’s profile on SEDAR prior to the Meeting for the most current information. In the event of any changes to the Meeting format due to the COVID-19 outbreak, the Corporation will **not** prepare or mail amended Meeting Proxy Materials.

**THE BOARD OF DIRECTORS AND MANAGEMENT REQUEST ALL SHAREHOLDERS VOTE BY PROXY AND NOT ATTEND THE MEETING IN PERSON. THE CONFERENCE NUMBER IS PROVIDED BELOW AND IT ENABLES SHAREHOLDERS TO PARTICIPATE IN A VOICE ONLY CONFERENCE CALL.**

In order to be valid and acted upon at the Meeting, proxies must be received not later than 11:00 a.m. (MST) on August 29, 2022 or not less than 48 hours (excluding Saturdays, Sundays and statutory holidays) before the time for holding the Meeting or any postponement(s) or adjournment(s) thereof. Failure to so deposit a form of proxy will result in its invalidation. Notwithstanding the foregoing, the chair of the Meeting has the discretion to accept proxies received after such deadline.

*Shareholders who are unable to attend the Meeting are requested to **COMPLETE AND SIGN THE ACCOMPANYING FORM OF PROXY** and forward it in the enclosed envelope by mail to the Corporation’s transfer agent, Computershare Trust Company of Canada, Attn: Proxy Department, 8<sup>th</sup> Floor, 100 University Avenue, Toronto, Ontario M5J 2Y1, or by fax within North America at 1-866-249-7775, or outside North America at (416) 263-9524, not later than 11:00 a.m. (MST) on **Monday, August 29, 2022**, or 48 hours (excluding Saturdays, Sundays and holidays) prior to the commencement or any adjournment of the Meeting, in order for such proxy to be used at the Meeting, or any adjournment(s) thereof.*

The form of proxy confers discretionary authority with respect to: (a) amendments or variations to the matters of business to be considered at the Meeting; and (b) other matters that may properly come before the Meeting. As at the date hereof, management of the Corporation knows of no amendments, variations or other matters to come before the Meeting other than the matters set out in this Notice of Meeting. Shareholders who are planning on returning the accompanying form of proxy are encouraged to review the Management Information Circular carefully before submitting the form of proxy.

Dated at Oakville, Ontario on July 26, 2022.

**BY ORDER OF THE BOARD OF DIRECTORS**

(Signed) *"Thomas A. Smeenk"*

**Thomas Smeenk,**  
President, Chief Executive Officer  
Hemostemix Inc.